KNSA.NASDAQ
- Kiniksa Pharmaceuticals International, plc
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.75/1.11
|
|
企業價值
3.48B
|
| 資產負債 |
|
每股賬面淨值
7.42
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
677.56M
|
|
每股收益
3.25
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |

44.9 
